Last reviewed · How we verify
NCT03497013
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
NA trial testing Active tDCS in Tardive Dyskinesia in 64 participants. Completed in 11 August 2020.
11 August 2020
Quick facts
| Lead sponsor | Suzhou Psychiatric Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 64 |
| Start date | 31 July 2017 |
| Primary completion | 11 August 2020 |
| Estimated completion | 11 August 2020 |
| Sites | 2 locations across China |
Drugs / interventions tested
- Active tDCS
- Sham tDCS
Conditions studied
- Tardive Dyskinesia — all drugs for Tardive Dyskinesia →
Sponsor
Suzhou Psychiatric Hospital
Who can join
Adults 18 to 70, any sex, with Tardive Dyskinesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study was to evaluate the efficacy, safety, and cognitive function of transcranial direct current stimulation (tDCS) in chronic schizophrenia patients with tardive dyskinesia (TD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and safety of Transcranial Direct Current Stimulation (tDCS) on cognitive function in chronic schizophrenia with Tardive Dyskinesia (TD): a randomized, double-blind, sham-controlled, clinical trial.
Zhou Y, Xia X, Zhao X, Yang R, et al · · 2023 · cited 11× · PMID 37620825 · DOI 10.1186/s12888-023-05112-0
Verify or expand the search:
- PubMed search for NCT03497013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Active tDCS
Trials testing the same drug.
- NCT07246993 — Targeting Neuroplasticity for Persistent Post-Concussive Cognitive Symptoms · NA · recruiting
- NCT07404319 — Effectiveness of Exercise Alone and tDCS+Exercise on Cognitive Function Improvement in Patients With Treatment Resistant · NA · not yet recruiting
- NCT07212829 — The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pai · NA · not yet recruiting
- NCT07202455 — Effect of Early Neuromodulation Coupled With Rehabilitation on the Prevention of Post-stroke Pain · NA · not yet recruiting
- NCT06901687 — Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) · Phase 2 · recruiting
Other recruiting trials for Tardive Dyskinesia
Currently open trials in the same condition.
- NCT07173920 — Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localizat · NA · recruiting
- NCT03495024 — Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates · Phase 4 · recruiting
Other Suzhou Psychiatric Hospital trials
Trials by the same sponsor.
- NCT03273439 — A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03497013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Suzhou Psychiatric Hospital
- Last refreshed: 24 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03497013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing